Cargando…

CB11, a novel purine-based PPARɣ ligand, overcomes radio-resistance by regulating ATM signalling and EMT in human non-small-cell lung cancer cells

BACKGROUND: Peroxisome proliferator-activated receptor γ (PPARγ) agonists frequently induce cell death in human non-small-cell lung cancer (NSCLC) cells. However, majority of NSCLC patients acquire resistance after cancer therapy, and it is still unclear. METHODS: In this study we investigated the a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Tae Woo, Hong, Da-Won, Park, Joung Whan, Hong, Sung Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723055/ https://www.ncbi.nlm.nih.gov/pubmed/32958825 http://dx.doi.org/10.1038/s41416-020-01088-w

Ejemplares similares

A novel PPARɣ ligand, PPZ023, overcomes radioresistance via ER stress and cell death in human non-small-cell lung cancer cells
por: Kim, Tae Woo, et al.
Publicado: (2020)

CB13, a novel PPARγ ligand, overcomes radio-resistance via ROS generation and ER stress in human non-small cell lung cancer
por: Kim, Tae Woo, et al.
Publicado: (2020)

PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions
por: Ercolano, Giuseppe, et al.
Publicado: (2021)

Therapeutic Effects of Targeted PPARɣ Activation on Inflamed High-Risk Plaques Assessed by Serial Optical Imaging In Vivo
por: Choi, Jah Yeon, et al.
Publicado: (2018)

FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines
por: Warrick, Joshua I., et al.
Publicado: (2016)

Beyond radio-displacement techniques for Identification of CB(1) Ligands: The First Application of a Fluorescence-quenching Assay
por: Bruno, Agostino, et al.
Publicado: (2014)

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
por: Stewart, C. Allison, et al.
Publicado: (2017)

Novel Ligands for a Purine Riboswitch Discovered by RNA-Ligand Docking
por: Daldrop, Peter, et al.
Publicado: (2011)

DDRE-24. TARGETING PURINE METABOLISM TO OVERCOME GLIOBLASTOMA THERAPY RESISTANCE
por: Zhou, Weihua, et al.
Publicado: (2021)

Expression and Function of Cannabinoid Receptors CB1 and CB2 and Their Cognate Cannabinoid Ligands in Murine Embryonic Stem Cells
por: Jiang, Shuxian, et al.
Publicado: (2007)

Riboswitch structure: an internal residue mimicking the purine ligand
por: Delfosse, Vanessa, et al.
Publicado: (2010)

MRE11 UFMylation promotes ATM activation
por: Wang, Zhifeng, et al.
Publicado: (2019)

The aPKCι blocking agent ATM negatively regulates EMT and invasion of hepatocellular carcinoma
por: Ma, C Q, et al.
Publicado: (2014)

Haploinsufficiency of Bcl11b suppresses the progression of ATM-deficient T cell lymphomas
por: Pinkney, Kerice A., et al.
Publicado: (2015)

PB01 suppresses radio-resistance by regulating ATR signaling in human non-small-cell lung cancer cells
por: Kim, Tae Woo, et al.
Publicado: (2021)

ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest
por: Scotto, Luigi, et al.
Publicado: (2020)

Overcoming EMT-driven therapeutic resistance by BH3 mimetics
por: Keitel, Ulrike, et al.
Publicado: (2014)

Substituted Purines as High-Affinity Histamine H(3) Receptor Ligands
por: Espinosa-Bustos, Christian, et al.
Publicado: (2022)

Epigenetic regulation of RARB overcomes the radio-resistance of colorectal carcinoma cells via cancer stem cells
por: Shu, Yuxian, et al.
Publicado: (2022)

The role of CB(2) receptor ligands in human eosinophil function
por: Frei, Robert, et al.
Publicado: (2012)

Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB(2) Receptor
por: Morales, Paula, et al.
Publicado: (2020)

MRE11 and ATM AKTivate pro-survival signaling
por: Golding, Sarah E., et al.
Publicado: (2011)

The Purins
por: Hopkins, Henry Reed
Publicado: (1910)

Thermal Polymorphism in CsCB(11)H(12)
por: Černý, Radovan, et al.
Publicado: (2023)

The Neuro-Protective Effects of the TSPO Ligands CB86 and CB204 on 6-OHDA-Induced PC12 Cell Death as an In Vitro Model for Parkinson’s Disease
por: Monga, Sheelu, et al.
Publicado: (2021)

Using triple radio-immunotherapy to overcome cancer immunotherapy resistance
por: Zhang, Zengfu, et al.
Publicado: (2023)

Detection of cancer stem cells by EMT-specific biomarker-based peptide ligands
por: Chen, Yi-An, et al.
Publicado: (2021)

Targeting purine metabolism in ovarian cancer
por: Liu, Jingchun, et al.
Publicado: (2022)

Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
por: Du, Bowen, et al.
Publicado: (2016)

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
por: Raoof, Sana, et al.
Publicado: (2019)

Role of ATM in the telomere response to the G-quadruplex ligand 360A
por: Pennarun, Gaëlle, et al.
Publicado: (2008)

THE PURINES AND PURINE METABOLISM OF SOME TUMORS IN DOMESTIC ANIMALS
por: Long, Esmond R.
Publicado: (1913)

ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
por: Mellone, Massimiliano, et al.
Publicado: (2022)

FAK system: Pulsing into CB test resistor R11
por: Metzmacher, K D
Publicado: (1974)

RETRACTED ARTICLE: Modulation of the TGF-β1-induced epithelial to mesenchymal transition (EMT) mediated by P1 and P2 purine receptors in MDCK cells
por: Zuccarini, Mariachiara, et al.
Publicado: (2017)

Down-Regulation of EBV-LMP1 Radio-Sensitizes Nasal Pharyngeal Carcinoma Cells via NF-κB Regulated ATM Expression
por: Ma, Xiaoqian, et al.
Publicado: (2011)

Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors
por: El-Atawneh, Shayma, et al.
Publicado: (2022)

Aggressiveness of non-EMT breast cancer cells relies on FBXO11 activity
por: Bagger, Sofie Otzen, et al.
Publicado: (2018)

TRIM11 Upregulation Contributes to Proliferation, Invasion, and EMT of Hepatocellular Carcinoma Cells
por: Zhang, Zewei, et al.
Publicado: (2017)

ATM-JAK-PD-L1 signaling pathway inhibition decreases EMT and metastasis of androgen-independent prostate cancer
por: Zhang, Lan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n3c551nmeb6s70nt8h4usir7rh